DME Capital Management LP Buys New Shares in Acadia Healthcare Company, Inc. (NASDAQ:ACHC)

DME Capital Management LP acquired a new stake in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 128,640 shares of the company's stock, valued at approximately $5,101,000. Acadia Healthcare comprises approximately 0.3% of DME Capital Management LP's portfolio, making the stock its 25th biggest holding. DME Capital Management LP owned about 0.14% of Acadia Healthcare at the end of the most recent quarter.

Several other large investors have also modified their holdings of ACHC. Bridgefront Capital LLC acquired a new stake in Acadia Healthcare during the fourth quarter worth about $276,000. Captrust Financial Advisors raised its holdings in Acadia Healthcare by 66.5% in the fourth quarter. Captrust Financial Advisors now owns 12,784 shares of the company's stock valued at $507,000 after buying an additional 5,108 shares during the period. Balyasny Asset Management L.P. acquired a new position in Acadia Healthcare during the fourth quarter valued at approximately $43,092,000. Ameriprise Financial Inc. increased its position in shares of Acadia Healthcare by 209.0% in the fourth quarter. Ameriprise Financial Inc. now owns 431,225 shares of the company's stock worth $17,098,000 after acquiring an additional 291,671 shares in the last quarter. Finally, Algert Global LLC purchased a new position in shares of Acadia Healthcare in the 4th quarter valued at $334,000.

Acadia Healthcare Stock Performance

Shares of ACHC opened at $24.16 on Thursday. The firm's 50 day moving average is $26.80 and its 200-day moving average is $36.91. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.07 and a quick ratio of 1.07. The stock has a market capitalization of $2.23 billion, a P/E ratio of 7.92, a P/E/G ratio of 1.46 and a beta of 1.01. Acadia Healthcare Company, Inc. has a 12-month low of $20.36 and a 12-month high of $82.41.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ACHC. Mizuho reduced their price objective on Acadia Healthcare from $48.00 to $37.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 25th. Royal Bank of Canada dropped their target price on Acadia Healthcare from $64.00 to $43.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Barclays lowered Acadia Healthcare from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $43.00 to $35.00 in a research report on Friday, February 28th. Guggenheim began coverage on Acadia Healthcare in a research note on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price for the company. Finally, KeyCorp dropped their price target on Acadia Healthcare from $70.00 to $65.00 and set an "overweight" rating on the stock in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Acadia Healthcare currently has a consensus rating of "Moderate Buy" and an average target price of $50.39.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.